After paying 2.24 million lei (€0.51 million) on November 16 for 0.77% of Zentiva, the majority shareholder acquired another 0.20% interest.
The median price paid by the drug maker for the 825,000 shares was 0.7lei/share, similar to the IPO price, transactions totaling 596,742 lei (€139,400). Sanofi Aventis’ stake in Zentiva has thus increased to 79.28%.
French-based drug maker reported a profit of 3.21 million lei (€0.76 million) for the three quarters ending September 30, 7 times lower than the same period of last year, which indicates a 5.33 million lei loss in the third quarter 2009.
Zentiva has a share capital of 41.69 million lei, divided into 416.9 million shares at a face value of 0.1lei.
The company’s current market value is 291.87million lei (€68 million), according to Friday’s closing quote of 0.7lei/share.
In lipsa unui acord scris din partea InternetCorp, puteti prelua maxim 500 de caractere din acest articol daca precizati sursa si daca inserati vizibil linkul articolului Sanofi Aventis pays EUR140,000 for 0.20% of Zentiva.